Nurix Therapeutics, Inc. (NRIX) — Analyst outlook / Analyst consensus target is. Based on 17 analyst ratings, the consensus is bullish — 17 Buy.
The consensus price target is $31.22 (low: $28.00, high: $36.00), representing an upside of 91.5% from the current price $16.30.
Analysts estimate Earnings Per Share (EPS) of $-2.81 and revenue of $0.06B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.88 vs est $-2.81 (missed -2.5%). 2025: actual $-3.05 vs est $-3.04 (missed -0.3%). Analyst accuracy: 99%.
NRIX Stock — 12-Month Price Forecast
$31.22
▲ +91.53% Upside
Average Price Target
Based on 17 Wall Street analysts offering 12-month price targets for Nurix Therapeutics, Inc., the average price target is $31.22, with a high forecast of $36.00, and a low forecast of $28.00.
The average price target represents a +91.53% change from the last price of $16.30.
Highest Price Target
$36.00
Average Price Target
$31.22
Lowest Price Target
$28.00
NRIX Analyst Ratings
Buy
Based on 17 analysts giving stock ratings to Nurix Therapeutics, Inc. in the past 3 months
EPS Estimates — NRIX
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.88
vs Est –$2.81
▼ 2.4% off
2025
Actual –$3.05
vs Est –$3.04
▼ 0.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — NRIX
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.055B
vs Est $0.055B
▼ 0.1% off
2025
Actual $0.084B
vs Est $0.085B
▼ 1.5% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
